Figure 3. Transcriptomic alterations by the early and late NaHS treatments. (A) Schematic of the early and late NaHS treatments in relation to their untreated controls. 100 μM of NaHS were used for each dosing. (B, C) The volcano plots represent DEGs of indicated controls and treatments. (D, E) The bubble charts representing KEGG enrichment analysis of indicated DEGs. The rich factor indicates the degree of enrichment represented by the ratio of DEGs in a pathway to the number of total genes annotated to that pathway. (F) Comparison of enriched pathways in (D and E).